|
|
|
01.04.26 - 11:15
|
Mosaic Therapeutics appoints Dr Vince O′Neill, MD, as Head of R&D (Business Wire)
|
|
|
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic's Executive Leadership team
- Vince will lead research and development for Mosaic's drug combination programs, including the build-out of the Company's early pipelineCAMBRIDGE, England--(BUSINESS WIRE)--Mosaic Therapeutics, Ltd, ('Mosaic', or 'the Company') a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O'Neill as Head of Research and Development (R&D) to support its next phase of growth.
“We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company's evolution,” said Thomas Fuchs, CEO, Mosaic Therapeutics. “His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.”
Vince is a board-certified medical oncologi...
|
|
|
|
|
|
|
26.03.26 - 15:02
|
Wall Street Cuts Mosaic Company Again: UBS Slashes Target to $27 (24/7 Wall St.)
|
|
|
The Mosaic Company (NYSE:MOS) received a downgrade from UBS on Thursday, as analyst Lucas Beaumont cut his rating to Neutral from Buy and slashed his price target to $27 from $33. The move reflects a structural squeeze on phosphate profitability — one that multiple Wall Street firms have now flagged in rapid succession. Ticker Firm ... Wall Street Cuts Mosaic Company Again: UBS Slashes Target to $27
The post Wall Street Cuts Mosaic Company Again: UBS Slashes Target to $27 appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
24.03.26 - 15:24
|
MOS Trades at 14x Earnings While Its Brazil Business Just Grew EBITDA 190% In Q3 2025 (24/7 Wall St.)
|
|
|
Mosaic (NYSE:MOS) is trading near its 52-week low after shares fell about 14% over the past week and about 13% over the past month. The catalyst was a Q4 2025 net loss of $519.5 million, driven by surging sulfur costs and a $189 million impairment charge. Yet full-year 2025 net income came in at $540.7 ... MOS Trades at 14x Earnings While Its Brazil Business Just Grew EBITDA 190% In Q3 2025
The post MOS Trades at 14x Earnings While Its Brazil Business Just Grew EBITDA 190% In Q3 2025 appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|
18.03.26 - 13:18
|
Mosaic’s Rare Earths Bet Could Revalue the Stock: What That Means for Investors (24/7 Wall St.)
|
|
|
Mosaic (NYSE: MOS) has spent most of its public life trading on fertilizer cycles. The five-year return of −14.9% reflects that reality. Then, on March 11, the stock jumped 10% in a single session on news that had nothing to do with potash or phosphate prices. The catalyst was a joint venture with Rainbow Rare ... Mosaic's Rare Earths Bet Could Revalue the Stock: What That Means for Investors
The post Mosaic's Rare Earths Bet Could Revalue the Stock: What That Means for Investors appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
